ACOG Alpha Cognition Inc

$ACOG The CONVERGE study demonstrates high real-world tolerability with an 80% target dose achievement rate among long-term care patients. This validates ZUNVEYL’s GI-friendly prodrug mechanism, providing crucial commercial leverage for broader physician adoption and PBM coverage.

$ACOG Management is having a virtual meeting with B Riley on Sept. 29. I think this will be a very positive corporate update in my opinion.

$ACOG Amidst another quarter of double digit growth. $14-$20 by EOY. Likely a BO candidate between $30-$50 2027. Higher if it lasts until 2028.

$ACOG Crazy that ACOG is still this unknown. In a year this will be a billion dollar company and that just will be the start.

$ACOG One of the most important points to consider relative to the data seen in the Converge study is that it helps patients get off of and/or reduce their "multi drug cocktail".

$ACOG FYI - There is a new major investor here - MANCHESTER MANAGEMENT CO LLC loaded approx. 52% more shrs to an ownership of 7.4%!!

$ACOG It is significant that Opaleye bought more shares recently. My guess is that they know that the launch is going well.

$ACOG announced inducement stock options for a new employee under Nasdaq Rule 5635(c)(4).

$ACOG Don't worry guys, I recently sold some shares so ACOG will probably squeeze in a couple of days now :D

$ACOG problem here is the company dont announce anything, no study complete, no ex us approval, no top line results.